09-08-2018 дата публикации
Номер: US20180221399A1
Принадлежит:
Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer. 25-. (canceled)6. A combination kit comprising the composition as claimed in claim 1 , together with at least one pharmaceutically acceptable carrier.7. A pharmaceutical composition comprising the composition as claimed in claim 1 , together with at least one component chosen from: a pharmaceutically acceptable diluent claim 1 , a carrier claim 1 , and an excipient.911-. (canceled)12. A method of treating cancer in a human in need thereof comprising administering the composition as claimed in .13. A method of treating cancer in a human in need thereof comprising administering the pharmaceutical composition as claimed in .14. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered at the same time.15. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered sequentially claim 13 , in any order.16. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are administered via a systemic intravenous dose.17. The method as claimed in claim 13 , wherein the anti-cancer agent is administered intravenously and the TLR4 agonist claim 13 , CRX-601 claim 13 , is administered intratumorally.18. The method as claimed in claim 13 , wherein the anti-cancer agent is administered intratumorally and the TLR4 agonist claim 13 , CRX-601 claim 13 , is administered intravenously.19. The method as claimed in claim 13 , wherein the anti-cancer agent and the TLR4 agonist claim 13 , CRX-601 claim 13 , are both administered intratumorally.20. The method as claimed in claim 13 , wherein the cancer is a solid tumor.21. The method as claimed in ...
Подробнее
